Successful conservative treatment for massive uterine bleeding with non-septic disseminated intravascular coagulation after termination of early pregnancy in a woman with huge adenomyosis: case report. by KIMURA Fuminori et al.
Successful conservative treatment for massive
uterine bleeding with non-septic disseminated
intravascular coagulation after termination of
early pregnancy in a woman with huge
adenomyosis: case report.
著者 KIMURA Fuminori, Takahashi Akimasa, KITAZAWA
Jun, YOSHINO Fumi, KATSURA Daisuke, AMANO
Tsukuru, MURAKAMI Takashi
journal or
publication title
BMC Women's Health
volume 20
number 1
page range 56
year 2020-03-19
URL http://hdl.handle.net/10422/00012641
doi: 10.1186/s12905-020-00924-8(https://doi.org/10.1186/s12905-020-00924-8)
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits
use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons
licence, and indicate if changes were made. The images or other third party material in this article
are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to
the material. If material is not included in the article's Creative Commons licence and your intended
use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit
http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated in a credit line to the data.
CASE REPORT Open Access
Successful conservative treatment for
massive uterine bleeding with non-septic
disseminated intravascular coagulation
after termination of early pregnancy in a
woman with huge adenomyosis: case
report
Fuminori Kimura*, Akimasa Takahashi, Jun Kitazawa, Fumi Yoshino, Daisuke Katsura, Tsukuru Amano and
Takashi Murakami
Abstract
Background: Adenomyosis is a benign gynecological condition in which endometrial tissue or endometrial-like
tissue develops within the uterine myometrium. Few cases of disseminated intravascular coagulation has been
reported in the patients with adenomyosis. Although hysterectomy is indicated for refractory massive uterine
bleeding in the patients with advanced uterine adenomyosis, conservative treatment is often desired in women in
the late reproductive age. Recently such cases are increasing due to the social trend of late marriage.
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Case presentation: A 37-year-old woman with huge adenomyosis, gravida 2 para 0, was referred to our hospital to
terminate her pregnancy. Acute, non-septic, disseminated intravascular coagulation (DIC) developed after early
pregnancy was terminated in a woman with huge adenomyosis. Massive bleeding and DIC occurred 3 days after
the dilatation and curettage. There was no evidence of infection as the cause of the DIC, because neither bacteria
nor endotoxin could be detected in her blood, and antithrombin 3 (AT3), which would be expected to decrease in
septic patients, was not decreased. Hemorrhage in the adenomyotic tissue after the termination presumably
developed inflammation, with numerous microthrombi and necrosis in the adenomyotic tissue, which subsequently
promoted coagulation and fibrinolysis, leading to the onset of massive uterine bleeding and DIC. Although severe
hyperfibrinolysis is observed in peripheral blood, the fibrinolysis state in the uterine myometrium is considered to
be even more severe. The newly formed clots for hemostasis under the uterine mucosa could be removed due to
the excessive activation of fibrinolytic system happened in the adjacent myometrium, leading to the onset of
massive uterine bleeding. Massive bleeding and DIC resolved quickly after the patient was treated with nafamostat
mesilate, which is effective for both excessive coagulation and fibrinolysis.
Conclusions: Adenomyosis could cause massive bleeding and DIC when pregnancy is terminated. Massive
bleeding was considered to occur because the excessive fibrinolysis system inside adenomyosis affected the
adjacent endometrium. Before considering hysterectomy to control refractory uterine bleeding, nafamostat mesilate
should be considered as one option, thinking the pathophysiology of the massive bleeding due to uterine
adenomyosis.
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Background
Disseminated intravascular coagulation (DIC) is a coagu-
lopathy that can occur in a large number of clinical con-
ditions, including malignant tumors and obstetrical
events [1–5]. However, few cases of DIC have been re-
ported in benign diseases, especially intrauterine diseases
[6–8]. Adenomyosis is a benign gynecological condition
in which endometrial tissue or endometrial-like tissue
develops within the uterine myometrium [9–11]. A case
of non-septic DIC that occurred after termination of
early pregnancy in a woman with huge adenomyosis is
presented. The DIC occurred during the period when
levels of pregnancy-related hormones and substances
were diminishing. The clinical course strongly suggested
that the massive bleeding was related to the occurrence
of excessive fibrinolysis. Although hysterectomy is indi-
cated for massive uterine bleeding in patients with ad-
vanced uterine adenomyosis, conservative treatment is
often desired in women in the reproductive age. Re-
cently, such cases have been increasing due to the social
trend of late marriage. The administration of nafamostat
mesilate, which is effective for both excessive coagula-
tion and fibrinolysis, should be considered as one option
when massive bleeding caused by excessive fibrinolysis
due to huge adenomyosis occurs in patients who want
to preserve their uterus.
Case presentation
A 37-year-old woman, gravida 2, para 0, was referred to
our hospital for termination of early pregnancy. She suf-
fered from huge adenomyosis and had been treated with
a GnRH agonist for 15 months in total. She also had a
history of transfusion due to severe uterine hemorrhage
when a miscarriage occurred at the age of 33 years.
On initial ultrasonography examination, the total
thickness of her uterus was found to be over 10 cm, and
extensive distribution of heterogeneous echogenicity was
diffusely detected in both the posterior and anterior
walls, as well as at the fundus. A 3-cm gestational sac
with fetal heart movement, compatible with a gestational
age of 6 weeks, was also detected in the uterine cavity
(Fig. 1). In Japan, women have right to terminate preg-
nancy in early stage because of the socio-economic rea-
son. In the present case, the woman was not married at
that time and wanted to terminate the pregnancy due to
financial reason. She was admitted, with dilatation and
curettage performed gently under ultrasonographic guid-
ance after the length of the uterine cavity was estimated
to be 8.5 cm with a sonde, which was not very enlarged.
There was little bleeding during the procedure. To pre-
vent infection, 1 g of cefmetazole (CMZ) was adminis-
tered intravenously twice in the perioperative period.
The patient recovered well and was discharged the next
day. When the patient was reviewed in the morning 3
days after the procedure, she had slight uterine bleeding
with no pain or fever. Laboratory tests were as follows:
white blood cells (WBCs) 8.0 × 103 (3.3 × 103–9.0 × 103/
μl), hemoglobin (Hb) 8.8 (11.5–15.0 g/dl), platelets 24 ×
104 (12 × 104 – 40 × 104 /μl), C-reactive protein (CRP)
0.9 mg/dl (< 0.5 mg/dl), anti-thrombin 3 (AT3) 108 (80–
130%), thrombin antithrombin III complex (TAT) 10.9
(< 3.0 ng/ml), D-dimer 6.1 (< 1.0 μg/ml), plasminogen
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activator inhibitor-1 (PAI-1) 91.4 (< 50 ng/ml), and plas-
min α2-plasmin inhibitor complex (PIC) 0.8 (0.4–0.8 μg/
ml) (Fig. 2a, b). However, she developed abdominal pain
that night, and the symptom gradually worsened. The
amount of uterine bleeding also increased dramatically.
She consulted our hospital again 5 days after the proced-
ure because of severe abdominal pain and massive uter-
ine bleeding. Her body temperature was 37.1 °C. There
was marked tenderness of the uterus, and massive uter-
ine bleeding continued. Her WBC count was 19.2 × 103/
μl, and her platelet count was decreased to 5.3 × 104 /μl.
Other laboratory tests were as follows: Hb 7.5 g/dl, CRP
24.1 (< 0.5 mg/dl), AT3 87%, TAT 36.0 ng/ml, D dimer
111.1 μg/ml, PAI-1 27.3 ng/ml, and PIC 13.7 μg/ml (Fig.
2a, b). These findings strongly suggested that the patient
was developing DIC. Endotoxin was not detected in her
blood, and no bacterial colonies grew in peripheral blood
and uterine blood cultures. The Chlamydia trachomatis
antibody titer was also not elevated. She was re-admitted
to hospital and treated with nafamostat mesilate (200
mg/day) for 60 h, which has effects against both exces-
sive coagulation and fibrinolysis, and cefmetazole (2 g/
day) for 2 days. A decrease in bleeding was observed in a
few hours. There was rapid improvement of her symp-
toms of abdominal pain and uterine bleeding and the la-
boratory data (Fig. 2a, b). Without surgical intervention,
the patient was discharged on the fourth days after the
second admission.
Discussion and conclusions
In the present case, the clinical course and laboratory
data strongly suggested that the DIC was unrelated to
infection. First, symptoms of abdominal pain usually
persist for several days after the start of treatment in the
case of severe uterine infection, but the symptoms di-
minished rapidly after the administration of cefmetazole
and nafamostat mesilate in the present case. Second, no
colonies grew or were detected on peripheral blood and
uterine blood cultures, and endotoxin was neither de-
tected in her blood. Third, the serum level of AT3 was
not decreased so much, and PAI-1 was not increased
when the patient complained of abdominal ache,
whereas these parameters should be markedly decreased
and markedly elevated, respectively, in a case of septic
DIC. Accordingly, mechanisms other than infection are
thought to have been responsible for her DIC. Thus,
adenomyosis was thought to be the main cause of DIC
after the termination of early pregnancy, although it is
difficult to reliably deny other causes.
Adenomyosis is a benign condition, but it is known to
cause hypermenorrhea, dysmenorrhea, and infertility [9–
11]. Hypermenorrhea may be due to increased area of
the uterine cavity, disturbance of uterine contraction,
and hemorrhage from the adenomyosis tissue to the
uterine cavity [12]. Inflammation and hemorrhage are
known as potential causes of dysfunctional coagulation
and fibrinolysis [13–15]. Recently, the occurrence of
DIC in a patient with adenomyosis during menstruation
was reported [7]. This report suggested that local
hemorrhage inside the adenomyosis and subsequent
thrombosis formation contributed to the development of
acute DIC. We recently reported activation of the fibrin-
olysis system during menstruation and its relationship to
microthrombi inside adenomyosis in patients with large
adenomyosis, and we suggested that intramural
hemorrhage in the adenomyosis lesion blocked vessels,
Fig. 1 Ultrasound image of patient’s uterus at the first visit. The uterus was more than 10 cm in the thickness, and heterogeneous echogenicity
could be diffusely detected throughout the myometrium. The uterine cavity was not enlarged and was rather narrow. It contained a 3 cm of
gestational sac with fetal heart movement
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leading to multiple microthrombi and ischemic damage
to the myometrium, resulting in activation of the fibrin-
olysis system [16]. Although severe hyperfibrinolysis is
observed in peripheral blood, we speculate the fibrinolysis
state in the uterine myometrium is considered to be even
more severe. The newly formed clot for hemostasis under
the uterine mucosa could be removed due to the excess fi-
brinolytic substance(s) from the adjacent myometrium,
Fig. 2 a. Changes in hemoglobin levels, white blood cell counts, platelets counts and levels of antithrombin 3. At 3 days after the procedure, the
hemoglobin (Hb) level and the platelet count was slightly decreased from the initial data. The white blood cell (WBC) count and the level of
antithrombin 3 (AT3) was in normal range. At fifth day of post procedure, the Hb level was decreased and the platelet count was markedly
decreased. The WBC count was markedly increased although the level of AT3 was still in normal range. After the treatment of nafamostat
mesylate and cefmetazole, the data were recovered. b. Changes in levels of D-dimer, thrombin antithrombin3 complex, plasminogen activator
inhibitor-1 and plasminα2-plasmin inhibitor complex. The level of plasminogen activator inhibitor-1 (PAI-1) and the level of thrombin
antithrombin 3 complex (TAT) was increased by the third day after the procedure, while the level of D-dimer and the level of plasminα2-plasmin
inhibitor complex (PIC) were in normal range. The levels of D-dimer, TAT and PIC increased markedly on the fifth day although the level of PAI-1
started to decease. Treatment with nafamostat mesilate led to rapid improvement of the levels of D-dimer, TAT and PIC
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leading to the onset of massive uterine bleeding. Difficulty
of the treatment of uterine adenomyosis might be that
uterine adenomyosis produces fibrinolytic substances, that
directly effect on the endometrium that lies on adjacent
adenomyosis. Moreover, a similar adenomyosis case of
acute DIC that developed after dilation and curettage was
reported [8]. The clinical course improved after treatment
with tranexamic acid, blood transfusions, and subtotal
hysterectomy. The authors also stated that activation of
the coagulation system, microthrombus formation, myo-
metrial necrosis, exhaustion of coagulation factors, and
hyperfibrinolysis might play crucial roles in the develop-
ment of DIC [8].
In the present case, the increase of sex steroid hor-
mones due to pregnancy could have affected the adeno-
myosis tissue and resulted in the production of more
microthrombi than usual menstruation. The patient did
not complain of abdominal pain until 3 days after the
procedure. In addition, 3 days after the procedure, AT3
was in the normal range. The Hb level and platelet
count were slightly decreased, and PAI-1 was increased
to 91.4 ng/ml. TAT and D dimer increased slightly to
10.9 ng/ml and 6.1 μg/ml, respectively, while PIC was
unchanged. PAI-1 inhibits the serine protease tissue
plasminogen activator (tPA) and is thus an inhibitor of
fibrinolysis. As it inhibited activation of blood fibrinoly-
sis, DIC might not occur at that time. Five days after the
procedure, the Hb level and platelet count were de-
creased, and PAI-1 was decreased to 27.3 ng/ml in nor-
mal range. However, TAT was increased to 36.0 ng/ml,
and D dimer and PIC were increased to 111.1 μg/ml and
13.7 μg/ml, respectively, although AT3 was still in the
normal range. Based on these data, the patient could be
diagnosed as developing DIC with both excess coagula-
tion and fibrinolysis. We thought that a large number of
thrombi had already formed 3 days after the procedure.
Considering the changes of PIC and D dimer, fibrinolysis
was excessive with increased coagulation after 3 days of
the procedure. Therefore, we thought that a large num-
ber of microthrombi had formed inside the adenomyotic
tissue around 3 days after the procedure, which subse-
quently led to the rapid onset of DIC with excessive fi-
brinolysis. Since severe fibrinolysis dysfunction was
confirmed in the peripheral blood, it was presumed that
the fibrinolysis dysfunction inside the uterus was further
enhanced. For this reason, massive uterine bleeding oc-
curred, and it is thought that a rapid decrease in the Hb
level and a decrease in the platelet count were observed.
Four cases of cerebral infarcts associated with adeno-
myosis have been reported [17]. Interestingly, 2 of the 4
patients had systemic embolism, and another patient had
thrombi in the brachiocephalic trunk and left subclavian
artery. The levels of coagulation markers were reported to
be elevated in the acute phase. The authors speculated
that patients with adenomyosis might be potentially at risk
of developing infarcts associated with hypercoagulability
related to menstruation-related coagulopathy or increased
tissue factors. Moreover, a case of uterine infarction inside
uterine adenomyosis following biochemical pregnancy
was reported [18]. Necrotic myometrium due to focal
uterine infarction was suspected based on pelvic magnetic
resonance imaging.
In the present case, nafamostat mesilate was adminis-
tered because the coagulation function was still acti-
vated, and nafamostat mesilate has effects against both
excessive coagulation and fibrinolysis to prevent the de-
velopment of infarcts [19, 20]. Administration of hepa-
rins alone to fibrinolytic DIC (DIC with a strong
fibrinolytic activation) rather promotes bleeding [21–23].
Both gabexate mesilate (FOY) and nafamostat mesylate
are synthetic serine protease inhibitors and exhibit
antithrombin-independent anticoagulant activity [22–
26]. However, FOY does not have strong effect to inhibit
fibrinolytic activity. Nafamostat mesylate is characterized
by a strong effect of inhibiting not only the activation of
coagulation but also the activation of fibrinolysis [24–
26]. For this reason, it is an extremely effective thera-
peutic agent for fibrinolytic DIC. To treat excessive fi-
brinolysis, we could choose to administer a drug with
only antifibrinolytic action, such as tranexamic acid.
However, we thought that it might increase the risk of
developing infarcts. Nafamostat mesilate can be expected
to suppress new redundant production of microthrombi
inside adenomyotic tissue. In our view, a drug affecting
both coagulation and fibrinolysis should be considered
when massive bleeding occurs in patients with huge ade-
nomyosis. Moreover, nafamostat mesylate has a short
half-life of 5–8min and we can quickly switch treatment
strategy to surgery if it is judged to be ineffective [21,
27].
She was very grateful that she saved her uterus as she
was unmarried and desired to get a child in future.
To the best of our knowledge, this is the first report of
successful conservative treatment of acute non septic
DIC after termination of early pregnancy in a woman
with adenomyosis. The clinical course strongly suggested
that bleeding inside the adenomyotic tissue promoted
excessive coagulation and fibrinolysis, which was then
related to the development of DIC. Although severe
hyperfibrinolysis is observed in peripheral blood, the fi-
brinolysis state in the myometrium is considered to be
even worse. The newly formed clot for hemostasis under
the uterine mucosa could be removed due to the excess
fibrinolytic system in the adjacent myometrium and
could cause massive bleeding. This case serves as a
warning that adenomyosis might induce DIC with exces-
sive fibrinolysis after termination of pregnancy as a trig-
ger and the usefulness of nafamostat mesilate to treat it
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in patients with huge adenomyosis who want to preserve
their uterus. Before considering hysterectomy to control
refractory uterine bleeding, nafamostat mesilate should
be considered as one option, thinking the pathophysi-
ology of the massive bleeding due to uterine adenomyo-
sis. Conservative treatment can be considered in the
case of “women who wants to conserve her fertility”.
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